(Q53900097)

English

A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/11127250

A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/11127250

visceral leishmaniasis

1 reference

based on heuristic

inferred from title

sodium stibogluconate

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Thakur CP

1

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/11127250

Kanyok TP

2

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/11127250

Pandey AK

3

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/11127250

Sinha GP

4

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/11127250

Zaniewski AE

5

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/11127250

Houlihan HH

6

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/11127250

Olliaro P

7

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/11127250

publication date

1 July 2000

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/11127250

Transactions of the Royal Society of Tropical Medicine and Hygiene

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/11127250

94

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/11127250

4

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/11127250

429-431

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/11127250

Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2800%2990130-5

21 January 2018

Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2800%2990130-5

21 January 2018

The sensitivity of Leishmania species to aminosidine

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2800%2990130-5

21 January 2018

Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2800%2990130-5

21 January 2018

Aminosidine (paromomycin) in the treatment of leishmaniasis imported into the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2800%2990130-5

21 January 2018

Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2800%2990130-5

21 January 2018

The effect of antibiotics of the neomycin group on experimental cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2800%2990130-5

21 January 2018

Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2800%2990130-5

21 January 2018

Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: a randomized dose-finding clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2800%2990130-5

21 January 2018

A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2800%2990130-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0035-9203(00)90130-5

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/11127250

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 May 2018

http://europepmc.org/abstract/MED/11127250

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53900097&oldid=1584648500"